- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02121730
Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions (FRISC)
Identification of Key Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais, Normandy and Picardy Regions
Kidney transplantation is now the treatment of choice for end-stage renal disease (ESRD). Between 2800 and 3000 kidney transplants are performed each year in France and more than 33 000 patients are living with a functioning graft.
Preventing allograft rejection requires the use of immunosuppressive therapy, the intensity decreases as the distance from the day of transplantation. Unfortunately, treatment favors certain complications, including infectious and neoplastic. These represent a major cause of mortality in these patients. If the frequency of skin cancer is greatly increased in this population, that of solid tumors remains a concern. Approximately 20% of patients develop cancer after 10 years of graft , half non- skin cancers, the main risk factor is immunosuppressive therapy .
The aim of the study is to evaluate, in a large population of patients treated in 4 regions ( the Nord-Pas de Calais, the Upper and Lower Normandy and Picardy) risk factors (in particular the nature of the immunosuppressive treatment) of developing a neoplastic complication, skin cancers and solid tumors, after renal transplantation.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
A retrospective analysis of the previous 10 years, from 2002 to 2011 will be conducted. This study will better understand the epidemiology of these complications but also allow to identify risk factors associated, including demographic, environmental and related to immunosuppressive therapy.
Thereafter, we hope to implement preventive measures or prospective studies, allowing us to reduce the prevalence of this complication.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Amiens, Francia, 80000
- Reclutamiento
- CHU Amiens
-
Investigador principal:
- Gabriel Choukroun, MD, PhD
-
Caen, Francia, 14000
- Aún no reclutando
- CHU Caen
-
Contacto:
- Bruno Hurault de Ligny, MD, PhD
- Correo electrónico: huraultdeligny-b@chu-caen.fr
-
Investigador principal:
- Bruno Bruno Hurault de Ligny, MD, PhD
-
Lille, Francia, 59000
- Aún no reclutando
- CHRU Lille
-
Contacto:
- Marc HAZZAN, MD, PhD
- Correo electrónico: m-hazzan@chru-lille.fr
-
Investigador principal:
- Marc Hazzan, MD, PhD
-
Rouen, Francia, 76000
- Aún no reclutando
- CHU Rouen
-
Contacto:
- Michel GODIN, MD, PhD
- Correo electrónico: michel.godin@chu-rouen.fr
-
Investigador principal:
- Michel Godin, MD, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- All adult renal transplant patients in the 4 centers of interregion North - West
- Patients transplanted during the period from 1 January 2002 and 31 December 2011
- Patients recipients of first, second or third renal transplantation
- Patients transplant recipients from a living or deceased donor whatever the immunological risk
- Eligible patients will be included after being informed by their doctor and after accepting their data to be processed in the framework of this study
- Patient with a health insurance coverage
Exclusion Criteria:
- Patients transplanted as child
- Patients transplanted before 1 January 2002
- Patients followed in the interregion but transplanted in another center
- Patients recipients of a double transplant (two kidneys or kidney plus other organ)
- Patients that do not accept their medical data to be included in the database
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Kidney Transplantation
Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Association between neoplastic complications and cancers
Periodo de tiempo: 10 years
|
Correlation, in a population of renal transplant patients followed in interregion Northwest, of the association of neoplastic complications after renal transplantation, skin cancers and solid tumors outside the non-Hodgkin's lymphoma and the terms of immunosuppressive treatment used
|
10 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Risk factors
Periodo de tiempo: 10 years
|
Identify the main risk factors for developing cancer after transplantation, besides immunosuppressive therapy
|
10 years
|
Incidence
Periodo de tiempo: 10 years
|
Evaluate the incidence of neoplastic complications after renal transplantation in interregion Northwest
|
10 years
|
Typology of cancers
Periodo de tiempo: 10 years
|
Assess the distribution and respective frequency of different types of cancer, skin and solid tumors in this group of patients
|
10 years
|
Survival prognosis
Periodo de tiempo: 10 years
|
Establish the prognosis and survival of transplanted patients with a diagnosis of cancer after transplantation
|
10 years
|
Survival factors
Periodo de tiempo: 10 years
|
Analyze the factors associated with the survival of transplanted patients who developed cancer after transplantation
|
10 years
|
Graft survival
Periodo de tiempo: 10 years
|
Evaluate graft survival in the group of patients who develop post- transplantation cancer , especially after cancer diagnosis
|
10 years
|
Rejection number
Periodo de tiempo: 10 years
|
Determine the number of cellular acute rejection and humoral rejections in patients who developed cancer and those free from this complication and analyze the prevalence of releases in the period following the diagnosis of cancer
|
10 years
|
Renal function after cancer
Periodo de tiempo: 10 years
|
To analyze the evolution of renal function after cancer diagnosis
|
10 years
|
Cancer management
Periodo de tiempo: 10 years
|
Analyze the management of these cancers, in particular as regards the strategy of immunosuppressive therapy after cancer diagnosis
|
10 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Gabriel Choukroun, MD, PhD, CHU Amiens
- Silla de estudio: Marc Hazzan, MD, PhD, CHRU Lille
- Silla de estudio: Bruno Hurault de Ligny, MD, PhD, CHU Caen
- Silla de estudio: Michel Godin, MD, PhD, CHU Rouen
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PI2012_843_0006
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de Riñón
-
Queens College, The City University of New YorkReclutamientoPublicación de artículos enviados al American Journal of Public HealthEstados Unidos
-
Children's Healthcare of AtlantaTerminadoNiños que se sometieron a un trasplante de corazón antes de los 18 años | Atención recibida en Children's Healthcare of AtlantaEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos